| Paul Gill, MD | |
|
333 Pine Ridge Blvd, Wausau, WI 54401-4102 | |
| (715) 847-2160 | |
| Not Available |
| Full Name | Paul Gill |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 333 Pine Ridge Blvd, Wausau, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528422623 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 68178-20 (Wisconsin) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Entity Name | Aspirus Wausau Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922321140 PECOS PAC ID: 6406757442 Enrollment ID: O20040114000297 |
News Archive
American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System. The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.
Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.
WHO today issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result.The move aims to ensure that decisions related to the safety and efficacy of vaccines, drugs and medical devices for use by populations are supported by the best available evidence.
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Gill, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: () - | Paul Gill, MD 333 Pine Ridge Blvd, Wausau, WI 54401-4102 Ph: (715) 847-2160 |
News Archive
American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System. The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.
Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.
WHO today issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result.The move aims to ensure that decisions related to the safety and efficacy of vaccines, drugs and medical devices for use by populations are supported by the best available evidence.
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.
› Verified 9 days ago
Stewart Michael Wente, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Winston D Ryan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Bartholomew D Hobson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2727 Plaza Dr, Wausau, WI 54401 Phone: 715-847-3000 | |
Dr. Andrew Joseph Stoltze, M.D., J.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 | |
Dr. Elizabeth Jeannie Wilson-ward, MD, FACEP Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3621 S Emerald Dr, Wausau, WI 54401 Phone: 715-845-9805 | |
Mark J Mirick, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 333 Pine Ridge Blvd, Wausau, WI 54401 Phone: 715-847-2121 |